SuspendedPhase 2
Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment
Key facts
- Who runs it
- University of California, San Diego
- Where
- La Jolla, United StatesSee the site
- Trial code
- Status
- Suspended
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 15 Feb 2023
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional, 4 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- THC ~2.5%
- THC ~5%
- THC ~10%
- Sham Cannabis
- Record updated
- 16 March 2026
- Why it stopped
- Inadequate funding
Who can take part
- Age
- 21 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age ≥ 21 and ≤ 65
- Able to communicate in English
- Migraine, with or without aura, in its episodic or chronic manifestations, as per the International Headache Society (IHS) classification International Classification of Headache Disorders (ICHD-3) criteria (section 1.1, 1.2, 1.3).(48)
- Ability to provide informed consent and complete website questionnaires in English
- Agrees not to use cannabis outside of the study during participation in the study
- Agrees not to use opioids or barbiturates during participation in the study
- Agrees not to drive a motor vehicle within 4.5 hours following last use of inhaled cannabis during participation in the study
Who cannot take part
- Positive urine drug test for THC, barbiturates, opioids, oxycodone, or methadone prior to enrollment
- Known cognitive impairment
- Current or past history of bipolar depression, schizophrenia, or psychosis
- Current or past history of cannabis, alcohol, opioid, or amphetamine abuse or other substance use disorder at the discretion of the research team
- Active pulmonary disease, class IV heart failure, cirrhosis, or other severe medical illnesses at the discretion of the research team
- Allergy to cannabis
- Pregnancy
- Breastfeeding
- Prisoner
- Institutionalized
- Current moderate-severe or severe depression
Where in United States
- Center for Pain Medicine, UC San DiegoLa Jolla, United StatesNo longer taking part
About the trial
What the trial wants to find out
This pilot crossover study will evaluate 3 different potencies of inhaled cannabis (2.5%, 5%, and 10%) and inhaled placebo cannabis for the acute treatment of migraine.
The 4 groups in the trial
- THC ~2.5%Treatment being tested
Inhalation of cannabis flower containing THC \~2.5%
- THC ~5%Treatment being tested
Inhalation of cannabis flower containing THC \~5%
- THC ~10%Treatment being tested
Inhalation of cannabis flower containing THC \~10%
- Sham CannabisSham treatment, for comparison
Inhalation of cannabis flower from which the THC and CBD have been extracted
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Inhaled Cannabis Versus Placebo for the Acute Treatment of Migraine: a Pilot, Randomized, Double-blind, Placebo-controlled, Crossover, Dose-ranging Trial
- Record updated
- 16 March 2026